Acclaim comes on the heels of RepRegen's CE marking approval for StronBone™, the first product of the company's platform to repair and regenerate hard tissue, such as bone
RepRegen™, the 'smart biomaterials' company that is a spin-out from Imperial Innovations plc, announced today that it has been recognized as one of the UK's 'Top 50 University Spin-out Companies' by Britain's largest-selling1 daily newspaper, The Daily Telegraph, which "has begun tracking the progress of 50 highly promising university spin-outs to show the breadth of cutting-edge technology emerging from Britain's universities."
Last month, RepRegen announced that it has received CE marking approval for StronBone™ bioactive glass with Strontium, the first product that will be commercialized from the company's repair-and-regeneration platform of 'smart' biomaterials for hard tissue, such as bone.
"It's great that RepRegen is being recognized for its achievements by one of the UK's, and the world's, foremost newspapers," said Ian Brown, RepRegen's CEO.
"We expect 2010 to be the breakout year for RepRegen," added Chairman Dr. Stephen Rietiker.
About RepRegen™ Ltd.
RepRegen™ Ltd. is a medical device company that uses patent-pending repair and regeneration technology platforms designed to mend and regrow hard tissue such as bone and soft tissue such as cartilage. A spin-out from Imperial Innovations plc and headquartered within the Imperial College Incubator, RepRegen is poised to commercialize the initial product of its hard tissue repair and regeneration platform: StronBone™ Bone Graft Substitute. Other products on the hard tissue repair and regeneration runway are targeted for orthopedic (trauma, spine) and craniomaxillofacial applications. The one-of-a-kind properties of RepRegen's platforms are designed to enable faster and superior tissue repair and regeneration. The Company's 'smart' biomaterials are designed to support and enhance natural cellular growth and tissue regeneration in vivo. These unrivaled materials are comprised of bioactive ceramics or biomimetic fibrous polymer scaffolds. A major RepRegen materials science innovation is the use of Strontium, which boosts performance of bioceramics for bone repair. Both of RepRegen's platforms — the hard and the soft tissue technologies — include a portfolio of new and unique products with performance characteristics that are designed to yield competitive advantages, including (1) Enhanced cellular growth properties for better and faster healing; and (2) Diversified structures tailored for a variety of porosities and configurations for specific applications.
NOTE: StronBone™ Bone Graft Substitute is an investigational device in the USA and limited by federal law to investigational use only.In the EU, StronBone™ Bone Graft Substitute has received CE marking approval.
1 Source: Wikipedia
Contacts:
Ronald Trahan Associates Inc.
Ronald Trahan, APR, 508-359-4005, x108
